Hypoactive Sexual Desire Disorder in Women Discussed by GMD in In-demand Research Report Available at MarketPublishers.com
04 May 2017 • by Natalie Aster
LONDON – Hypoactive sexual desire disorder (HSDD) refers to chronic or continuous lack of interest in sexual activity among women, to the extent that it causes their personal distress or problems in their relationships.
The precipitating factors comprise anxiety, depression, hypoandrogenism, and chronic debilitating diseases, like chronic kidney disease, hyperprolactinemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.
Emotional Brain BV, Apricus Biosciences, GlaxoSmithKline, Valeant Pharmaceuticals International, and Palatin Technologies are the leading companies engaged in the development of the drug products used for the treatment of HSDD.
In-demand research report “Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017” elaborated by GMD examines the female HSDD pipeline landscape.
The research gives an unprejudiced overview of the therapeutic scenario for female HSDD (women's health) worldwide. It canvasses the therapeutics development of this disorder, gives a detailed overview of the overall pipeline overview alongside reviewing the pipeline by companies and universities/research organisations, and examines the products under development by companies. The research study features pipeline products based on the different stages of development; assesses female HSDD therapeutics by target, MoA, RoA, and molecule type; and covers elaborate drug profiles for the pipeline products which encompass, product description, revealing licensing and collaboration details, R&D outline, MoA, among other activities.
Furthermore, the report discusses the key companies involved in the development of female HSDD therapeutics, contains a listing of all their leading and minor projects, as well as casts light on the emerging players with possibly strong product portfolio. The pipeline guide also encloses all the dormant and discontinued pipeline projects, reviews the latest news with respect to pipeline therapeutics for HSDD.
More in-demand research reports by GMD are available at its page.